United States
Print page content Print
Increase text size Decrease text size
Text Size

LINCOMIX®

(lincomycin) TYPE A MEDICATED ARTICLE

HEALTHIER PIGS. IMPROVED ECONOMIC OUTCOMES.

Mycoplasma hyopneumoniae (M. hyopneumoniae) has challenged swine veterinarians and producers for decades, and the disease remains a legitimate challenge. Various surveys suggest U.S. herd prevalence exceeds 50%,1 and according to recent research from Iowa State University, M. hyopneumoniae was the third-most common cause of swine pneumonia from 2003 to 2014.

LINCOMIX from Zoetis is now approved at a range of 100 to 200 grams per ton for the reduction in severity of effects of respiratory disease associated with M. hyopneumoniae. It is the only U.S. Type A Medicated Article with an approved M. hyopneumoniae claim. When the product is administered at 100 g/ton, producers and veterinarians can also control ileitis.

CAUTION: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.

Reference:
1 Thacker EL, Minion FC. Mycoplasmosis. In: Zimmerman JJ, Karriker LA, Ramirez A, et al, eds. Diseases of Swine, 10th ed. Oxford, UK: Wiley-Blackwell; 2012:779-797.

Expand All
    • LINCOMIX is approved for both the reduction of severity of effects of respiratory disease associated with M. hyopneumoniae and for the control of ileitis.
    • LINCOMIX now has a broader dosage range for M. hyopneumoniae, allowing veterinarians and herd managers to manage M. hyopneumoniae based on feeding budgets and timing of symptoms.
    • LINCOMIX has a zero-day withdrawal requirement and no export restrictions.
    • LINCOMIX is backed by value-added services from Zoetis, including:
      • STOMP Diagnostics from Zoetis to both validate a VFD and to identify timing of the M. hyopneumoniae challenge so pigs are treated based on when the disease threat is greatest.
      • Nutritional services to help illustrate how LINCOMIX fits into your feeding ration.
      • Feed assays so you can be confident LINCOMIX is administered within rations as intended.
    • LINCOMIX is complemented by a broad range of M. hyopneumoniae management solutions from Zoetis, including vaccines and anti-infectives to help manage the disease based on each farm’s M. hyopneumoniae goals.
  • DOSAGE CLAIM
    40 g/ton For control of swine dysentery and for control of porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis. Feed as sole ration; for use in swine on premises with a history of swine dysentery but where symptoms have not yet occurred or following use of lincomycin at 100 g/ton for treatment of swine dysentery.
    100 g/ton For treatment of swine dysentery and for control of porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis. Feed as sole ration for 21 days or until signs of disease disappear.
    100 g/ton followed by 40 g/ton For the treatment and control of swine dysentery and the control of porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis. Feed as sole ration for 21 days or until signs of disease disappear.
    100 to 200 g/ton For the reduction in the severity of respiratory disease associated with Mycoplasma hyopneumoniae. Feed as sole ration for 21 days.

  • LINCOMIX Type A Medicated Article contains lincomycin and is available in concentrations of 20 and 50 grams of active ingredient per pound of premix. Both concentrations come packaged in 50-pound bags.

Do not use in swine intended for breeding. Do not allow unapproved species access to feeds containing lincomycin.

LIN-00025

CLICK IMAGES FOR MORE INFORMATION